scholarly journals Haplotype Association Mapping of Acute Lung Injury in Mice Implicates Activin A Receptor, Type 1

2011 ◽  
Vol 183 (11) ◽  
pp. 1499-1509 ◽  
Author(s):  
George D. Leikauf ◽  
Vincent J. Concel ◽  
Pengyuan Liu ◽  
Kiflai Bein ◽  
Annerose Berndt ◽  
...  
Author(s):  
M. I. Marushchak ◽  
I. M. Klishch ◽  
Yu. I. Bondarenko ◽  
L. P. Mazur

<p>Background. Current data suggest systemic autoimmune activation in the pathogenesis of bronchopulmonary<br />diseases. The imbalance in the system of pro- and anti-inflammatory cytokines is very important in<br />immunopathogenesis.<br />Objective. The aim of our research was to determine the caspase-3 rate in the dynamics of experimental<br />acute lung injury and to study the relationship between their level and the number of cells carrying membrane<br />binding TNF receptor type 1 to define the main mechanisms of cell death.<br />Results. The analysis of the results of caspase-3 rate in lung homogenate showed that this cysteine proteinase<br />was uniformly increasing in all experimental groups during simulating of ALI induced by administration of<br />hydrochloric acid (p&lt;0.001). When comparing the results of caspase course of apoptosis it was defined that,<br />despite the progressive increase in caspase-3 rate in lung homogenate, cysteine proteinase rate in plasma did<br />not change.<br />The receptor mechanism of apoptosis was studied by establishing correlation relationships with the number<br />of cells carrying membrane binding TNF type 1 (TNF-R1) receptor. A strong positive correlation relationship<br />between the number of neutrophils with TNF-R1 and caspase-3 rate in lungs of all research groups was<br />determined.<br />Conclusions. The implementation of neutrophils death by apoptosis is caused by change of activity of<br />caspase cascade effector components, such as caspase-3, in cases of ALI induced by intratracheal administration<br />of hydrochloric acid. One of the potential mechanisms responsible for the activation of caspase course is excessive<br />generation of active forms of oxygen and increase in the number of neutrophils carrying membrane binding TNF<br />receptor type 1.<br />KEY WORDS: caspase-3, tumour necrosis factor alpha receptor 1, acute lung injury</p>


2020 ◽  
Vol 528 (2) ◽  
pp. 299-304
Author(s):  
Jian-Bo Lin ◽  
Jian-Feng Chen ◽  
Fan-Cai Lai ◽  
Xu Li ◽  
Jin-Bao Xie ◽  
...  

2014 ◽  
Vol 28 (6) ◽  
pp. 2538-2550 ◽  
Author(s):  
Jennifer L. Nichols ◽  
Wesley Gladwell ◽  
Kirsten C. Verhein ◽  
Hye‐Youn Cho ◽  
Jürgen Wess ◽  
...  

2004 ◽  
Vol 286 (1) ◽  
pp. L156-L164 ◽  
Author(s):  
Richard P. Marshall ◽  
Peter Gohlke ◽  
Rachel C. Chambers ◽  
David C. Howell ◽  
Steve E. Bottoms ◽  
...  

Angiotensin II (ANG II), generated by activation of local renin-angiotensin systems, is believed to play an important role in tissue repair and remodeling, in part via transforming growth factor-β (TGF-β). Angiotensin-converting enzyme (ACE) inhibitors have been shown to abrogate experimental lung injury via a number of potential mechanisms; however, the potentially fibroproliferative role for ANG II in the lung has not been characterized. We hypothesized that, after lung injury, ANG II would stimulate fibroblast procollagen synthesis and promote lung collagen deposition in rats. In vitro, ANG II was a potent inducer of procollagen production in human lung fibroblasts via activation of the type 1 receptor and, at least in part, via the autocrine action of TGF-β. After bleomycin-induced lung injury, an increase in lung ANG II concentration was observed by day 3 that preceded increases in lung collagen and was maintained until death at day 21. Administration of an ACE inhibitor (ramipril) reduced ACE activity, ANG II concentration, TGF-β expression, and collagen deposition. Losartan (an ANG II type 1 receptor antagonist) also attenuated the increase in TGF-β expression and lung collagen deposition. These observations suggest that ANG II, possibly generated locally within the lung, may play an important role in the fibrotic response to acute lung injury, at least in part via the action of TGF-β. ACE inhibitors and receptor antagonists, already widely used clinically, should be assessed as potential new therapies for fibrotic lung disease.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Misako Shigematsu ◽  
Tomoaki Koga ◽  
Ayako Ishimori ◽  
Kazuko Saeki ◽  
Yumiko Ishii ◽  
...  

2020 ◽  
Author(s):  
Wan-Chung Hu

The global outbreak of COVID-19 has a detrimental impact on public health. COVID-19 is usually manifested as pneumonia which can progress into acute respiratory distress syndrome (ARDS). Currently, we have not yet a very successful therapeutic agent to manage this disease. The most promising drug, Remdesivir, has the effectiveness in 30% of SARS-CoV-2 infected patients. We still need effective agents to treat the coronavirus as well as to treat acute lung injury and other complications caused by this coronavirus. The host immunological pathway against virus is typically a THalpha/beta immune response. The THalpha/beta immunity is triggered by type 1 interferon and interleukin 27. The main effector cells of THalpha/beta immune response is interleukin 10 secreting CD4 T cells, CD8 T cells, NK cells, and IgG1 producing B cells. Besides, interleukin 10 has a potent immunomodulatory or anti-inflammatory effect. In addition, IL-10 is an anti-fibrotic agent to reduce fibrosis. Interleukin 10 can ameliorate acute lung injury or ARDS, especially caused by viruses. The pathogenesis of ARDS is overt immune activation in lung. Thus, I suggest to use interleukin 10 for the possible treatment agent for COVID-19.


Sign in / Sign up

Export Citation Format

Share Document